ScoreWhy is Gland Pharma Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0 times
2
Poor long term growth as Operating profit has grown by an annual rate 0.04% of over the last 5 years
3
Positive results in Dec 25
- NET SALES(Q) Highest at Rs 1,695.36 cr
- PBDIT(Q) Highest at Rs 434.88 cr.
- PBT LESS OI(Q) Highest at Rs 323.31 cr.
4
Stock is technically in a Mildly Bullish range
- The technical trend has improved from Sideways on 05-May-26 and has generated 31.55% returns since then
- Multiple factors for the stock are Bullish like MACD, Bollinger Band, KST and OBV
5
With ROE of 10.1, it has a Expensive valuation with a 3.7 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 52.57%, its profits have risen by 49.6% ; the PEG ratio of the company is 0.7
6
High Institutional Holdings at 40.65%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
7
Market Beating performance in long term as well as near term
- Along with generating 52.57% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Gland Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Gland Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Gland Pharma
56.63%
1.48
35.59%
Sensex
-11.8%
-0.49
12.94%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
12.50%
EBIT Growth (5y)
1.45%
EBIT to Interest (avg)
84.05
Debt to EBITDA (avg)
0.15
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.58
Tax Ratio
28.86%
Dividend Payout Ratio
42.46%
Pledged Shares
0
Institutional Holding
39.18%
ROCE (avg)
20.24%
ROE (avg)
10.76%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
44
Industry P/E
36
Price to Book Value
4.89
EV to EBIT
36.12
EV to EBITDA
27.17
EV to Capital Employed
6.53
EV to Sales
7.08
PEG Ratio
0.91
Dividend Yield
0.65%
ROCE (Latest)
16.56%
ROE (Latest)
10.09%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend17What is working for the Company
ROCE(HY)
Highest at 14.30%
NET SALES(Q)
Highest at Rs 1,800.27 cr
PBT LESS OI(Q)
At Rs 373.75 cr has Grown at 27.5% (vs previous 4Q average
PAT(Q)
At Rs 316.96 cr has Grown at 21.3% (vs previous 4Q average
-1What is not working for the Company
DEBTORS TURNOVER RATIO(HY)
Lowest at 3.40 times
Loading Valuation Snapshot...
Here's what is working for Gland Pharma
Net Sales - Quarterly
Highest at Rs 1,800.27 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 373.75 cr has Grown at 27.5% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 293.15 CrMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 316.96 cr has Grown at 21.3% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 261.23 CrMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Here's what is not working for Gland Pharma
Debtors Turnover Ratio- Half Yearly
Lowest at 3.40 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio
